SAN CARLOS, Calif., May 5, 2011 /PRNewswire/ -- PharmacoFore, Inc., a privately held biopharmaceutical company developing next-generation abuse-resistant prescription drugs, announced today that it is a sponsor of the 2011 CLAAD National Prescription Drug Abuse Prevention Policy Consensus Meeting, scheduled for November 29, 2011 in Washington, DC.
Wesley D. Sterman, M.D., president and CEO of PharmacoFore, Inc., stated, "PharmacoFore shares CLAAD's objective to prevent the misuse and abuse of prescription medications while ensuring adequate medical care for patients in need. When developing our abuse-resistant technologies, we focused on patient needs, including removing barriers to pain therapy by significantly reducing the risk of prescription drug abuse. We fully support CLAAD in its efforts."
40 national not-for-profit public health and safety organizations will attend the meeting to discuss policies to reduce prescription drug diversion, misuse and abuse while retaining medication access for legitimate patients. As a result of the meeting, CLAAD will update its recommendations for prescription monitoring program funding and optimization, and encourage improvements in overdose information collection. The federal government has recently adopted four of CLAAD's major prescription drug abuse prevention recommendations.
"Pharmaceutical companies have a societal obligation to make their products safer to address the prescription drug abuse epidemic. CLAAD is pleased to see that PharmacoFore is exploring new medications designed from their outset to deter abuse and overdose," said Michael C. Barnes, CLAAD founder and interim executive director. "We are delighted to welcome PharmacoFore to our coalition, and we look forward to continuing to coordinate policy and action with the company as a commercial partner."
The Center for Lawful Access and Abuse Deterrence (CLAAD), a not-for-profit organization, fosters collaboration among the multiple sectors of society to address the growing national concern for prescription drug abuse. Annually, CLAAD organizes a consensus meeting and conducts direct interviews to obtain input from stakeholders for its National Prescription Drug Abuse Prevention Strategy. The 2010 strategy can be downloaded at http://claad.org/downloads/2010_National_Strategy.pdf.
About PharmacoFore, Inc.
PharmacoFore, Inc., is a privately held biopharmaceutical company focused on creating novel medicines to improve upon the therapeutic utility of existing drugs, enhance patient care, and prevent the misuse, abuse, and overdose of prescription medications. The Company's novel Bio-Activated Molecular Delivery system (Bio-MDs), in contrast to current approaches, effectively addresses abuse via injection and inhalation, as well as abuse via the more common oral route (e.g., chewing pills prior to ingestion). PharmacoFore will announce the results of its Bio-MDs human proof-of-concept study in 2Q'11.
PharmacoFore has also created a complementary technology, MPAR(TM), which is uniquely applicable to drugs with its Bio-MDs' mechanism of activation. MPAR provides protection against oral overdose. When several doses of MPAR-protected drugs are co-ingested, the systemic exposure of the opioid drug is dramatically limited, without the use of opioid antagonists, such as naloxone, which may expose a patient to additional risks. Ultimately, PharmacoFore's technology will (1) provide patients with the best treatment option for moderate-to-severe pain; (2) address the worldwide under-treatment of pain; (3) offer a comprehensive solution to the rapidly growing global issue of prescription drug abuse, and; (4) for the first time, provide protection against oral routes of abuse.
About Prescription Drug Abuse
Prescription drug abuse and addiction are major burdens to American society, resulting in significant costs, illness and deaths. More than 48 million Americans abuse prescription drugs in their lifetimes; in 2005, such abuse cost the government $467.7 billion.
According to the U.S. National Institutes of Health, pain affects more Americans than diabetes, heart disease, and cancer combined, with chronic pain being the most common cause of long-term disability. The U.S. economic impact of acute and chronic pain exceeds $100 billion per year.
PharmacoFore, Inc. Contact:
A. Gregory Sturmer
Tiberend Strategic Advisors, Inc.
VP, Finance and Chief Financial Officer
SOURCE PharmacoFore, Inc.